Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marieke F Fransen

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2013
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effectsMarieke F Fransen, Tetje C van der Sluis, Ferry Ossendorp, et al.
Clinical & Translational Immunology|January 17, 2022
Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapyMaurice van Duijvenvoorde, Sarah Derks, Idris Bahce, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 11, 2010
Separate roles for antigen recognition and lymph node inflammation in CD8+ memory T cell formationMarieke F Fransen, Marianne J van Stipdonk, Marjolein Sluijter, et al.
Molecular Imaging and Biology|January 4, 2023
Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging ApproachPhilipp Knopf, Dimitri Stowbur, Sabrina H L Hoffmann, et al.
Oncoimmunology|May 17, 2017
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapyJan Willem Kleinovink, Koen A Marijt, Mark J A Schoonderwoerd, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 10, 2015
Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulationSima Rahimian, Marieke F Fransen, Jan Willem Kleinovink, et al.
JCI Insight|December 7, 2018
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapyMarieke F Fransen, Mark Schoonderwoerd, Philipp Knopf, et al.
JTO Clinical and Research Reports|September 8, 2023
Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLCEzgi B Ulas, Sayed M S Hashemi, Ilias Houda, et al.
Cancer Research|August 3, 2005
CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hostsAnnemieke Th den Boer, Geertje J D van Mierlo, Marieke F Fransen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 2004
The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environmentAnnemieke Th den Boer, Geertje J D van Mierlo, Marieke F Fransen, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2013
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effectsMarieke F Fransen, Tetje C van der Sluis, Ferry Ossendorp, et al.
Clinical & Translational Immunology|January 17, 2022
Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapyMaurice van Duijvenvoorde, Sarah Derks, Idris Bahce, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 11, 2010
Separate roles for antigen recognition and lymph node inflammation in CD8+ memory T cell formationMarieke F Fransen, Marianne J van Stipdonk, Marjolein Sluijter, et al.
Molecular Imaging and Biology|January 4, 2023
Preclinical Identification Of Tumor-Draining Lymph Nodes Using a Multimodal Non-invasive In vivo Imaging ApproachPhilipp Knopf, Dimitri Stowbur, Sabrina H L Hoffmann, et al.
Oncoimmunology|May 17, 2017
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapyJan Willem Kleinovink, Koen A Marijt, Mark J A Schoonderwoerd, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 10, 2015
Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulationSima Rahimian, Marieke F Fransen, Jan Willem Kleinovink, et al.
JCI Insight|December 7, 2018
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapyMarieke F Fransen, Mark Schoonderwoerd, Philipp Knopf, et al.
JTO Clinical and Research Reports|September 8, 2023
Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLCEzgi B Ulas, Sayed M S Hashemi, Ilias Houda, et al.
Cancer Research|August 3, 2005
CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hostsAnnemieke Th den Boer, Geertje J D van Mierlo, Marieke F Fransen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 7, 2004
The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environmentAnnemieke Th den Boer, Geertje J D van Mierlo, Marieke F Fransen, et al.
Pageof 6